Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary) ; Dronabinol
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors SciSparc

    • Most Recent Events

    • 27 Sep 2024 Planned initiation date changed from 1 Feb 2024 to 1 Jan 2025.
    • 23 Sep 2024 According to a SciSparc media release, company has already secured the Institutional Review Board approvals from all three clinical sites, as well as approval from all related federal administrations.
    • 23 Sep 2024 According to a SciSparc media release, company announced that the U.S. Food and Drug Administration has confirmed that its investigational new drug (IND) application for its first in class drug candidate SCI-110 study may proceed with its Phase IIb clinical trials in the U.S. in adults patients with Tourette Syndrome.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top